TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Avalo Therapeutics ( (AVTX) ) has shared an update.
On October 29, 2025, Avalo Therapeutics announced the completion of patient enrollment for its Phase 2 LOTUS trial of AVTX-009, aimed at treating hidradenitis suppurativa. The trial exceeded its target with approximately 250 patients enrolled, reflecting strong engagement from both investigators and patients. This milestone brings Avalo closer to potentially offering a new treatment option for this chronic condition, with topline data expected in mid-2026.
The most recent analyst rating on (AVTX) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Avalo Therapeutics stock, see the AVTX Stock Forecast page.
Spark’s Take on AVTX Stock
According to Spark, TipRanks’ AI Analyst, AVTX is a Neutral.
Avalo Therapeutics’ overall stock score is primarily impacted by its poor financial performance, which reflects significant operational and profitability challenges. Despite strong technical indicators suggesting bullish momentum, the negative valuation metrics due to ongoing losses weigh heavily on the stock’s attractiveness.
To see Spark’s full report on AVTX stock, click here.
More about Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases. Their lead asset, AVTX-009, is in a Phase 2 clinical trial for hidradenitis suppurativa (HS), and the company is exploring additional opportunities in prevalent indications with significant unmet needs.
Average Trading Volume: 379,760
Technical Sentiment Signal: Sell
Current Market Cap: $241.7M
See more insights into AVTX stock on TipRanks’ Stock Analysis page.